Today's Rundown Featured Story | | | The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. |
|
|---|
|
|  | Download a recent study highlighting the root of key challenges clinical operations professionals are struggling with to complete their oversight responsibilities and the important solutions this study reveals. Read Now >> |
Top Stories Monday, February 24, 2020 GlaxoSmithKline has struck a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells. Monday, February 24, 2020 Last fall, NGM Bio unveiled data from a small group of patients showing its NASH drug cut liver fat in a phase 2 study. Now, the company is reporting results for all 78 patients in the study, showing the treatment beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup. Thursday, February 13, 2020 FierceBiotech sits down with some of the most informative industry leaders at JPM 2020. Monday, February 24, 2020 Kadmon has posted positive and more detailed data out of its so-called ROCKstar pivotal trial of KD025 in chronic graft-versus-host disease. Monday, February 24, 2020 Grifols has struck a deal to buy assets from bankrupt antibiotic developer Aradigm. The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets. Monday, February 24, 2020 University of Toronto researchers used a live-cell-based screening system to identify drugs that can enter cells and target EGFR mutations in lung cancer. In so doing, they discovered that Astellas’ Xospata and Novartis’ Rydapt, both approved to treat leukemia, may be useful in treating lung cancer patients who have developed resistance to EGFR inhibitors. Friday, February 21, 2020 The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics after serving on its board of directors for less than a year. Friday, February 21, 2020 Esperion has had a rocky road to approval for its LDL-cholesterol-lowering drug Nexletol after a late-stage trial in 2018 threatened to derail its quest. But after backing its drug up with strong safety data, Esperion has the green light to go to market. Resources Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Research Solutions / Reprints Desk Inc. 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates for Veeva, Workday, Microstrategy or any software platform by implementing the right methodology with a focus on behavior change. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
